NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $10.10 -0.07 (-0.69%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.99▼$10.2450-Day Range$9.20▼$13.2352-Week Range$8.25▼$19.43Volume16,867 shsAverage Volume87,255 shsMarket Capitalization$69.99 millionP/E RatioN/ADividend YieldN/APrice Target$46.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Precision BioSciences alerts: Email Address Precision BioSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside358.7% Upside$46.33 Price TargetShort InterestHealthy7.60% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.85Based on 7 Articles This WeekInsider TradingSelling Shares$24,218 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.99) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.13 out of 5 starsMedical Sector187th out of 936 stocksBiological Products, Except Diagnostic Industry23rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 2 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.60% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 7.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Precision BioSciences is -0.99. Previous Next 2.7 News and Social Media Coverage News SentimentPrecision BioSciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Precision BioSciences this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,218.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($2.99) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Precision BioSciences Stock (NASDAQ:DTIL)Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More DTIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DTIL Stock News HeadlinesJuly 25 at 6:18 PM | finance.yahoo.comStratus Networks Selects Precision Optical Technologies Passive Optical Network Access Solution -- OpenPath™ to Expand Fiber NetworkJuly 25 at 6:18 PM | msn.comTailoring Cancer Treatment to the Patient: The Importance of Biomarker Testing in Precision MedicineJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 25 at 6:18 PM | msn.comSona BLW Precision share price in focus after strong Q1 results. Here’s what brokerages sayJuly 25 at 6:18 PM | msn.comPEAK Precision Manufacturing to establish new facility in Bowling GreenJune 20, 2024 | businesswire.comPrecision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.June 5, 2024 | businesswire.comPrecision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver CongressMay 30, 2024 | businesswire.comPrecision BioSciences to Participate in Upcoming June Investor ConferencesJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 29, 2024 | finance.yahoo.comGS Precision and Jeh Aerospace Secure Significant Long-Term Manufacturing PartnershipMay 28, 2024 | tmcnet.comPrecision Neuroscience Announces World Record for Number of Electrodes Placed On Human BrainMay 27, 2024 | msn.comHere's what it's like inside the operating room when someone gets a brain implantMay 17, 2024 | businesswire.comPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | markets.businessinsider.comDeep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)May 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)May 14, 2024 | markets.businessinsider.comMaintaining Hold on Precision BioSciences Pending Clinical Data and Strategic ReassessmentsMay 14, 2024 | markets.businessinsider.comPrecision BioSciences Reports Profit From Cont. Ops. In Q1May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong FinancialsSee More Headlines Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CUSIPN/A CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$46.33 High Stock Price Target$60.00 Low Stock Price Target$19.00 Potential Upside/Downside+355.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($7.4651) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,320,000.00 Net Margins-48.10% Pretax Margin-34.74% Return on Equity-131.69% Return on Assets-22.73% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$48.73 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book2.25Miscellaneous Outstanding Shares6,930,000Free Float6,649,000Market Cap$70.48 million OptionableOptionable Beta1.74 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael Amoroso (Age 46)President, CEO & Director Comp: $1.07MMr. John Alexander Kelly R.Ph. (Age 57)CFO & Principal Accounting Officer Comp: $660.91kDr. Alan F. List M.D. (Age 69)Chief Medical Officer Comp: $692.17kDr. Jefferson J. Smith Ph.D. (Age 51)Co-Founder & Chief Research Officer Mei BurrisDirector of Investor Relations & FinanceMr. Dario Scimeca (Age 49)General Counsel & Secretary Comp: $576.43kMr. Bruce StevensVice President of Quality & ComplianceMaurissa MessierSenior Director of Corporate CommunicationsMs. Juli BlancheChief People OfficerMr. Garrett GincleyHead of ManufacturingMore ExecutivesKey CompetitorsSangamo TherapeuticsNASDAQ:SGMOFreeline TherapeuticsNASDAQ:FRLNTenaya TherapeuticsNASDAQ:TNYAMolecular PartnersNASDAQ:MOLNGenfitNASDAQ:GNFTView All CompetitorsInsiders & InstitutionsJ. Jefferson SmithSold 50 sharesTotal: $589.50 ($11.79/share)Dario ScimecaSold 93 sharesTotal: $1,096.47 ($11.79/share)Janus Henderson Group PLCBought 573,052 shares on 5/16/2024Ownership: 8.286%Vanguard Group Inc.Sold 4,493,945 shares on 5/10/2024Ownership: 3.771%Acadian Asset Management LLCSold 3,229,642 shares on 5/10/2024Ownership: 1.652%View All Insider TransactionsView All Institutional Transactions DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $10.95 on January 1st, 2024. Since then, DTIL shares have decreased by 7.8% and is now trading at $10.10. View the best growth stocks for 2024 here. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.10. The company earned $17.58 million during the quarter, compared to analysts' expectations of $9.35 million. Precision BioSciences had a negative trailing twelve-month return on equity of 131.69% and a negative net margin of 48.10%. When did Precision BioSciences' stock split? Precision BioSciences shares reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Matt Kane's approval rating as Precision BioSciences' CEO? 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU) and Homology Medicines (FIXX). This page (NASDAQ:DTIL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.